XC-103 by Ixchel Pharma for Friedreich Ataxia: Likelihood of Approval

June 5, 2023. XC-103 is under clinical development by Ixchel Pharma and currently in Phase I for Friedreich Ataxia. According to GlobalData, Phase I drugs for Friedreich Ataxia does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the IXC-103 LoA Report.